Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kristyna Zavacka"'
Autor:
Veronika Mancikova, Michaela Pesova, Sarka Pavlova, Robert Helma, Kristyna Zavacka, Vaclav Hejret, Petr Taus, Jakub Hynst, Karla Plevova, Jitka Malcikova, Sarka Pospisilova
Publikováno v:
Molecular Oncology, Vol 17, Iss 1, Pp 82-97 (2023)
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild‐type protein. We assessed the impact of p53 protein phosphorylat
Externí odkaz:
https://doaj.org/article/d23f7fd800de4b44a79aa2866eceb35e
Autor:
Kristyna Zavacka, Karla Plevova
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Chromothripsis represents a mechanism of massive chromosome shattering and reassembly leading to the formation of derivative chromosomes with abnormal functions and expression. It has been observed in many cancer types, importantly, including chronic
Externí odkaz:
https://doaj.org/article/4374ef7ff7ac4271b02f42a6e28a0dd0
Autor:
Veronika Mancikova, Michaela Pesova, Sarka Pavlova, Robert Helma, Kristyna Zavacka, Vaclav Hejret, Petr Taus, Jakub Hynst, Karla Plevova, Jitka Malcikova, Sarka Pospisilova
Publikováno v:
MOLECULAR ONCOLOGY
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild-type protein. We assessed the impact of p53 protein phosphorylatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94f83448458456a9ca3b6618bb055d3
https://doi.org/10.1002/1878-0261.13337
https://doi.org/10.1002/1878-0261.13337
Autor:
null Veronika Mancikova, null Michaela Pesova, null Sarka Pavlova, null Robert Helma, null Kristyna Zavacka, null Vaclav Hejret, null Petr Taus, null Jakub Hynst, null Karla Plevova, null Jitka Malcikova, null Sarka Pospisilova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c701c231e672495f249bb95db5df114
https://doi.org/10.1002/1878-0261.13337/v2/response1
https://doi.org/10.1002/1878-0261.13337/v2/response1
Autor:
Marcela Zenatova, Šárka Pospíšilová, Nikola Tom, Yvona Brychtová, Karla Plevová, Jitka Malčíková, Barbara Dvorackova, Šárka Pavlová, Jakub Hynšt, Jiri Mayer, Michael Doubek, Lenka Radová, Karol Pál, Boris Tichy, Kristyna Zavacka, Anna Panovská, Barbara Kunt Vonkova, Jana Kotašková, Eva Ondroušková
Publikováno v:
Blood
Patients with chronic lymphocytic leukemia (CLL) with TP53 mutations with a >10% variant allele frequency (VAF) are often refractory to chemotherapy and benefit from targeted therapy. Malcikova and colleagues correlated TP53 mutations with
Key P
Key P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9256fec657c01f658f2878cff713a6e
http://europepmc.org/articles/PMC8703362
http://europepmc.org/articles/PMC8703362
Autor:
Eva Ondroušková, Michaela Bohúnová, Kristýna Závacká, Patrik Čech, Petra Šmuhařová, Miroslav Boudný, Martina Oršulová, Anna Panovská, Lenka Radová, Michael Doubek, Karla Plevová, Marie Jarošová
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM, is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups with diver
Externí odkaz:
https://doaj.org/article/9874afffb5374bcba126ff413f2cbae2